Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2006-05-02
2006-05-02
Russel, Jeffrey Edwin (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S016700, C514S475000, C514S478000, C514S588000, C530S300000, C530S329000, C549S332000, C560S157000, C564S032000
Reexamination Certificate
active
07037890
ABSTRACT:
The present invention provides angiogenesis inhibitor compounds comprising a MetAP-2 inhibitory core coupled to a peptide, as well as pharmaceutical compositions comprising the angiogenesis inhibitor compounds and a pharmaceutically acceptable carrier. The present invention also provides methods of treating an angiogenic disease, e.g., cancer, in a subject by administering to the subject a therapeutically effective amount of one or more of the angiogenesis inhibitor compounds of the invention.
REFERENCES:
patent: 4703107 (1987-10-01), Monsigny et al.
patent: 5135919 (1992-08-01), Folkman et al.
patent: 5180735 (1993-01-01), Kishimoto et al.
patent: 5180738 (1993-01-01), Kishimoto et al.
patent: 5290807 (1994-03-01), Folkman et al.
patent: 5422363 (1995-06-01), Yanai et al.
patent: 5648382 (1997-07-01), Billington et al.
patent: 5698586 (1997-12-01), Kishimoto et al.
patent: 5767293 (1998-06-01), Oku et al.
patent: 5789405 (1998-08-01), Oku et al.
patent: 6017954 (2000-01-01), Folkman et al.
patent: 6086865 (2000-07-01), Folkman et al.
patent: 6548477 (2003-04-01), Olson et al.
patent: 2002/0193298 (2002-12-01), Olson et al.
patent: 0 354 767 (1990-02-01), None
patent: 0 357 061 (1990-03-01), None
patent: 0 359 036 (1990-03-01), None
patent: 0 387 650 (1990-09-01), None
patent: 0 415 294 (1991-03-01), None
patent: 0 415 294 (1991-03-01), None
patent: WO 98/13059 (1998-04-01), None
patent: WO 98/56372 (1998-12-01), None
patent: WO 9959986 (1999-11-01), None
patent: WO 9961432 (1999-12-01), None
patent: WO 00/64486 (2000-11-01), None
patent: WO 00/644486 (2000-11-01), None
patent: WO 0069472 (2000-11-01), None
Denmeade SR, et al. “Enzymatic activation of a doxorubicin-peptide prodrug by prostate-specific antigen.”Cancer Res. Jun. 15, 1998; 58(12):2537-40.
Griffith EC, et al. “Molecular recognition of angiogenesis inhibitors fumagillin and ovalicin by methionine aminopeptidase 2.”Proc Natl Acad Sci U S A. Dec. 22, 1998; 95(26):15183-8.
Griffith EC, et al. “Methionine aminopeptidase (type 2) is the common target for angiogenesis inhibitors AGM-1470 and ovalicin”.Chem Biol. Jun. 1997;4(6):461-71.
Han CK, et al. “Design and synthesis of highly potent fumagillin analogues from homology modeling for a human MetAP-2.”Bioorg Med Chem Lett. Jan. 3, 2000;10(1):39-43.
Landquist, JK “Some Degradation Products of Fumagillin”J. Chem. Soc. 1956: 4237-4245.
Tarbell et al. “The structure of fumagillin”Am. Chem. Soc. Feb 20, 1960: 82:1005-1007.
Liu S. et al. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. Nov. 13, 1998;(5392):1324-7.
Sin N, et al. “The anti-angiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2.”Proc Natl Acad Sci U S A. Jun. 10, 1997;94(12):6099-103.
Timar F, et al. “The antiproliferative action of a melphalan hexapeptide with collagenase-cleavable site.”Cancer Chemother Pharmacol. 1998;41(4):292-8.
Turk BE, et al. “Selective inhibition of amino-terminal methionine processing by TNP-470 and ovalicin in endothelial cells.”Chem Biol. Nov. 1999;6(11):823-33.
De Marre, A. et al. “Synthesis and evaluation of macromolecular prodrugs of mitomycin C,”Journal of Controlled Release36(1/2):87-97 (Sep. 1995).
Nichifor, M. et al. “Chemical and enzymatic hyrdolysis of dipeptide derivatives of 5-fluorouracil,”Journal of Controlled Release47:271-281 (1997).
Birktoft Jens
Cook Charles Michael
Lee Lily
Olson Gary L.
Self Christopher
DeConti Giulio A.
Laccotripe Zacharakis Maria
Praecis Pharmaceuticals Inc.
Russel Jeffrey Edwin
LandOfFree
Therapeutic agents and methods of use thereof for the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic agents and methods of use thereof for the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic agents and methods of use thereof for the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3624477